Baseline characteristics
| . | Data . |
|---|---|
| No. patients | 366 |
| Baseline FVIII activity, no. (%) | |
| Less than 0.01 IU/mL | 332 (91) |
| 0.01 to 0.02 IU/mL | 34 (9) |
| Ethnicity, no.(%) | |
| White | 327 (90) |
| African | 8 (2) |
| Asian | 15 (4) |
| Other | 15 (4) |
| Family history hemophilia, no. (%) | |
| Positive | 168 (47) |
| Negative | 191 (53) |
| Family history inhibitors, no. (%) | |
| Positive | 24 (15) |
| Negative | 138 (85) |
| FVIII gene mutation type, no. (%) | |
| Large deletions | 10 (3) |
| Nonsense mutations | 30 (10) |
| Inversions | 172 (55) |
| Small deletions/insertions | 41 (13) |
| Missense mutations | 49 (16) |
| Other | 10 (3) |
| Breastfeeding, no. (%) | |
| Yes | 91 (69) |
| No | 41 (31) |
| Median age at first exposure day, mo (IQR) | 11 (6-15) |
| Median age at 50th exposure day, mo* (IQR) | 31 (21-46) |
| Duration first and 50th exposure day, mo* (IQR) | 19 (12-32) |
| All peak treatment moments, no. (%) | |
| Yes | 251 (78) |
| No | 71 (22) |
| Major peak treatment moments, no. (%) | |
| Yes | 176 (55) |
| No | 146 (45) |
| Surgery during first 50 exposure d, no. (%) | |
| Yes | 80 (25) |
| No | 242 (75) |
| Treatment regimen, no. (%) | |
| Prophylaxis | 196 (55) |
| On demand | 162 (45) |
| Median age at start of prophylaxis, mo (IQR) | 20 (14-35) |
| Median no. exposure d at start of prophylaxis (IQR) | 16 (8-28) |
| Reason for first exposure to factor VIII, no. (%) | |
| Bleed | 286 (84) |
| Prophylaxis | 37 (11) |
| Surgery | 17 (5) |
| . | Data . |
|---|---|
| No. patients | 366 |
| Baseline FVIII activity, no. (%) | |
| Less than 0.01 IU/mL | 332 (91) |
| 0.01 to 0.02 IU/mL | 34 (9) |
| Ethnicity, no.(%) | |
| White | 327 (90) |
| African | 8 (2) |
| Asian | 15 (4) |
| Other | 15 (4) |
| Family history hemophilia, no. (%) | |
| Positive | 168 (47) |
| Negative | 191 (53) |
| Family history inhibitors, no. (%) | |
| Positive | 24 (15) |
| Negative | 138 (85) |
| FVIII gene mutation type, no. (%) | |
| Large deletions | 10 (3) |
| Nonsense mutations | 30 (10) |
| Inversions | 172 (55) |
| Small deletions/insertions | 41 (13) |
| Missense mutations | 49 (16) |
| Other | 10 (3) |
| Breastfeeding, no. (%) | |
| Yes | 91 (69) |
| No | 41 (31) |
| Median age at first exposure day, mo (IQR) | 11 (6-15) |
| Median age at 50th exposure day, mo* (IQR) | 31 (21-46) |
| Duration first and 50th exposure day, mo* (IQR) | 19 (12-32) |
| All peak treatment moments, no. (%) | |
| Yes | 251 (78) |
| No | 71 (22) |
| Major peak treatment moments, no. (%) | |
| Yes | 176 (55) |
| No | 146 (45) |
| Surgery during first 50 exposure d, no. (%) | |
| Yes | 80 (25) |
| No | 242 (75) |
| Treatment regimen, no. (%) | |
| Prophylaxis | 196 (55) |
| On demand | 162 (45) |
| Median age at start of prophylaxis, mo (IQR) | 20 (14-35) |
| Median no. exposure d at start of prophylaxis (IQR) | 16 (8-28) |
| Reason for first exposure to factor VIII, no. (%) | |
| Bleed | 286 (84) |
| Prophylaxis | 37 (11) |
| Surgery | 17 (5) |
*In noninhibitor patients.